Aromatase inhibitors (AIs) such as letrozole are effective therapies for post-menopausal women with breast cancer. However, their use has been associated with increased bone resorption markers and bone loss at the lumbar spine and total spine. A new study shows that upfront zolendronic acid in combination with letrozole offers the potential to combine the anti-cancer effect of letrozole with the bone protective effect of zolendronic acid.
Go to Previous Page
Go to Next Page